Compare Cytokinetics Inc (CYTK) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Valero Energy Corporation — how do they compare? Cytokinetics Inc trades at $76.44 (market cap $10.63B), while Valero Energy Corporation trades at $328 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 8.8× Cytokinetics Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VLO | |
|---|---|---|
Market Cap | $10.63B | $93.27B |
Sector | Technology | Energy |
52-Week High | $87.26 | $323.92 |
52-Week Low | $34.31 | $133.38 |
Enterprise Value | $10.74B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Valero Energy (VLO) trades at $314.95, up 5.58% in 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $307 and resistance at $324. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $12.54 surpassing the $10.11 estimate. Revenue for 2026 is projected to rise to $139.4 billion, with net income margin improving to 5.17%.
Outlook remains positive due to robust refining margins and renewable diesel growth, but risks include volatile oil prices and geopolitical tensions. Analysts maintain a buy consensus with a $324.27 price target, indicating potential upside. Investors should monitor execution on earnings guidance and global energy supply dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
